HealthQuill weight loss
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More
Obesity is a health risk that needs to be tackled worldwide
Health Medical

Weight loss offers health benefits, even if pounds creep back: Study

Bharti Jayshankar March 24, 2025: University of Gothenburg researchers have uncovered a silver lining for those who struggle to maintain weight loss. According.

Read More
GLP-1 based weight-loss drugs have some therapeutic benefits, but the risks are as high
Drugs Pharma Research

New insights on GLP-1 drugs: Benefits and risks unveiled

HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.

Read More
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a statement.
Uncategorized

Novo Nordisk says its drug CargiSema cuts body weight by 22.7% in adults

Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.

Read More
obesity
Health

Lilly’s trial results for treating obesity and pre-diabetes are promising

HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%, according to a statement from the Indianapolis-headquartered firm.
Drugs Health Pharma

Eli Lilly’s trial weight-loss drug reduces heart failure risk by 38%

Eli Lilly and Company’s Zepbound or trizepatide injection to treat obesity reduces the risk of heart failure, hospitalisation and cardiovascular death by 38%,.

Read More